In recent years we have seen a slow but steady paradigm shift in how pharmaceutical companies approach early drug discovery. The role of discovery partnerships in a high-failure-rate industry such as bio/pharma is thus pivotal for enhancing innovation while de-risking in the pre-clinical stages. In this interview Kristof Van Emelen, Scientific Director - Partnership Integrator for Janssen Pharmaceutica N.V., speaks to Andrea Charles from Pharma IQ about impact of the rise of global innova...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
AI for Pharma & Healthcare
23 - 25 September, 2025
Amsterdam
Register Now |
View Agenda |
Learn More